Right ventricular failure (RVF) is associated with significant morbidity and mortality. There is an increasing interest in proper assessment of right ventricle (RV) function as well as understanding mechanisms behind RVF.
INTRODUCTION
For many years, the right heart and its potential role in disease had been largely ignored. Observations from patients with Fontan circulation who could live for periods without heart failure symptoms contributed to the belief that the right heart was essentially nothing more than a passive conduit. These patients in fact did do well, until the systemic ventricle began to fail or pulmonary hypertension developed -both situations in which right ventricle (RV) afterload is increased. It is now evident that the function of the right heart is directly related to outcomes in many disease states, including pulmonary arterial hypertension (PAH) [1, 2] , heart failure with reduced [3,4 & ]. The International Right Heart Foundation Working Group recently proposed a comprehensive definition of right heart failure: 'a clinical syndrome due to an alteration of structure and/or function of the right heart circulatory system that leads to suboptimal delivery of blood flow (high or low) to the pulmonary circulation and/or elevated venous pressures-at rest or with exercise' [8 & ]. Although the RV is a very important part of the right heart system (and the main focus of this article), failure of any component of the circulation, from the systemic veins up to the pulmonary capillaries, can result in right heart failure symptoms.
THE NORMAL RIGHT VENTRICLE
The normal RV is a thin-walled crescent-shaped structure that is composed of the RV-free wall, interventricular septum and RV outflow tract. Although it is a distinct embryologic structure from the left ventricle (LV), the interventricular septum has shared fibers with the LV [9] . As a consequence of these shared fibers, the LV accounts for as much as 30-50% of RV contractile function [10] . The septum itself, via its efficient longitudinal/twisting contraction, contributes most to overall RV function as
The causes of RV failure (RVF) are many and varied, but LV failure remains the leading cause ( Table 1 ). The same factors that lead to left-sided dysfunction can also impact the RV, causing intrinsic RV dysfunction. RV contractility may further be reduced because the RV depends on the LV for a substantial portion of its function.
The RV normally ejects blood into a low afterload, highly compliant arterial circuit. When afterload is increased, especially acutely, a marked reduction in RV function can occur [12] . Elevated left-sided filling pressures not only increase pulmonary pressure passively but also lower vascular compliance, thereby augmenting pulsatile RV afterload [13] . Over time, LV failure may also precipitate pulmonary arterial vasoconstriction and/or remodeling, further elevating afterload. In some cases of chronic or slowly progressive elevations in afterload, the RV is able to compensate relatively well, as is the case with Eisenmenger's syndrome [14 & ]. In others, it is not. Continued efforts are underway to diagnose and predict the development of RVF secondary to increased left-sided filling pressures, most particularly as it complicates implantation of LVADs. With increased understanding of cardiomyocyte dysfunction in pulmonary hypertension and RVF, it is worth reviewing the advances made in the past year on molecular signaling in the failing RV.
Molecular changes in the right ventricle
There is increasing appreciation and acceptance of the metabolic changes that develop in the failing
RV [15
& ], and this has been particularly well studied in PAH-associated RVF. In RVF, a metabolic shift from mitochondrial oxidative phosphorylation to cytoplasmic glycolysis has been identified as the RV undergoes hypertrophy, as evidenced by increased uptake of fluorodeoxyglucose-PET scan [16] and by direct measurement of metabolism in an RV working heart model [17 & ]. This increase in glycolysis is accompanied by a decrease in fatty acid oxidation, referred to as the Warburg effect, a phenomenon that has traditionally been used in discussing metabolism of cancer cells [18] , and is mediated by hyperpolarized mitochondrial membrane potential. In PAH, the accompanying increase in RV afterload creates an ischemic RV, due at least in part to compromised right coronary artery blood flow [19] . Furthermore, there is observed capillary rarefaction in the RV of patients with PAH, most particularly with sclerodermaassociated PAH [17 & ].
In the setting of an ischemic myocardium, mitochondria-dependent apoptosis is suppressed and there is decreased production of mitochondria-
KEY POINTS
Comprehensive assessment of RV function is difficult as it requires consideration of both RV contractility and afterload (RV-PA coupling).
RV contractile reserve is prognostic in pulmonary hypertension and may identify patients with uncoupling at rest. RVF has a very poor prognosis and no standardized treatment options are available. RVF is accompanied by increased glycolysis, decreased glucose oxidation and increased glutaminolysis, and these abnormalities in metabolism are mediated through mitochondrial dysfunction. derived reactive oxygen species (mROS), potentially to minimize stress in a hypertrophying myocardium [20 & ]. Although the RV remains compensated, there is an increase in hypoxia-inducible factor 1a (HIF1a), which may promote angiogenesis to counteract the increased O 2 demands of a hypertrophied RV. When the RV becomes decompensated, there is an increase in mROS, a decrease in HIF1a and a decrease in glucose oxidation. In this setting, patients with PAH enter into a syndrome of pronounced RVF, especially as the decrease in HIF1a is accompanied by decreased angiogenesis and exacerbation of ischemia in the RV [20 & ].
Additive to the cancer phenotype is the recent observation that there is an increase in glutaminolysis within the RV of patients and animals with PAH
]. Glutaminolysis is the metabolism of glutamine, which in cancer allows rapid cell growth without apoptosis [22] . In right ventricular hypertrophy (RVH), capillary rarefaction and RV ischemia activate the proto-oncogene cMyc that increases glutamine uptake and in turn increases production of a-ketoglutarate. a-Ketoglutarate then enters the Krebs cycle, producing malate. This Krebs cyclederived malate then generates cytosolic pyruvate, which in turn is converted by lactate dehydrogenase A to lactate. In the setting of increased glutaminolysis, this is accompanied by inhibition of glucose oxidation. This maladaptive pathway has the potential to be therapeutically manipulated by inhibitors of glutaminolysis, which would then optimize cellular metabolism in the failing RV by increasing glucose oxidation.
Peroxisome proliferator-activated receptorgamma coactivator 1a (PGC-1a) governs a large number of genes that regulate mitochondrial function [23 & ] and has been shown to be downregulated in the failing RV [24 & ]. This decreased expression of RV PGC-1a results in a loss of mitochondrial protein and oxidative capacity. In fact, not only is this decrease in PGC-1a associated with decreased mitochondrial number, but also the mitochondria become hyperpolarized, abnormally shaped and have a reduced adenosine diphosphate (ADP)stimulated (state 3) rate for complex I [24 & ]. These structural and functional abnormalities of the RV mitochondria provide credence to the theory of mitochondrially mediated metabolic abnormalities in the failing RV and offer therapeutic potential in the form of metabolic modulators such as the pyruvate dehydrogenase kinase inhibitor dichloroacetate, which is currently the study of clinical trials in PAH (http://clinicaltrials.gov/show/NCT01083524).
There is ongoing debate and controversy regarding the sequence of events in the RV, namely the timing of mitochondrial dysfunction as it relates to the development of RVF [25], but it is apparent that the glycolytic shift that occurs in the RV is a maladaptive response and can ultimately contribute to the 'burning out' of the RV [25] . Furthermore, the loss of the angiogenic program contributes to the loss of capillaries that contributes to ischemia, and the loss of mitochondrial hyperpolarization facilitates myocardial apoptosis, which can potentially thin out the RV and contribute to RV decompensation and failure [20 & ].
ASSESSMENT OF RIGHT VENTRICULAR FUNCTION

Noninvasive measures
Accurate and comprehensive assessment of RV function remains a challenge. ]. Strain imaging is increasingly being utilized to assess RV function. Strain is likely a composite measure of RV loading and dysfunction, and as such abnormal strain patterns likely develop from microvascular ischemia (Table 1) as well as myocardial disarray from distension of the RV. Sachdev et al.
[34] studied RV longitudinal strain in 80 patients with PAH and discovered that worse RV strain was associated with disease progression, higher diuretic use and mortality. Although risk scores have traditionally focused on clinical parameters [35] to predict RVF after LVAD implantation, more recent efforts have concentrated on using echocardiographic strain assessments of the RV to risk stratify patients. In this setting, RV strain patterns have been shown to add incremental benefit on top of clinical risk scores [36] . Free wall RV longitudinal strain also best predicts clinical outcomes in patients referred for heart transplantation, when compared with N-terminal pro-brain natriuretic peptide (BNP), global strain patterns, LV ejection fraction and other echocardiographic parameters [37 & ]. Additionally, in groups 1, 3 and 4 pulmonary hypertension, RV longitudinal peak systolic strain as assessed and measured by speckle-tracking echocardiography can predict survival even when adjusted for invasive hemodynamics, and RV strain provides incremental prognostic value over conventional echocardio ] recently demonstrated that RV longitudinal strain measured by echocardiogram correlated with MRI-derived RVEF but only correlated moderately with MRI-derived strain. This latter finding suggests strain measures may not be interchangeable among imaging modalities. Routine assessment of RV strain in patients with risk factors and/or diseases that can predispose to RVF may become a necessary skill to develop in echocardiography laboratories over the next few years.
Cardiac MRI has become the gold standard for noninvasive assessment of RV function and is the most accurate method for determining RV mass, volume and ejection fraction (EF) [42 & ]. van de Veerdonk et al. [1] found a change in RVEF, assessed by MRI, was the variable most predictive of outcome in patients receiving PAH-specific therapy. In another study by the same group, increases in RV size and declining RVEF predicted clinical worsening in patients with idiopathic PAH [43 & ]. Investigators from the multicenter EURO-MR study have shown that on-treatment changes in RV (especially RVEF) and LV parameters predict improvement in functional capacity [44 & ]. As in PAH, lower RVEF portends a worse outcome in left heart failure [3, 45] .
Invasive hemodynamics
Hemodynamic variables obtained via right heart catheterization may aid in assessing right heart function. Elevated right atrial pressure and low cardiac index are associated with worse survival in historical and more modern cohorts of PAH [46, 47] . However, one must remember that factors other than RV dysfunction may contribute to elevations in right atrial pressure, including pericardial constraint [48] . Elevation in pulmonary vascular resistance (PVR) (>3 Wood units) is associated with poor prognosis in left heart disease [ In left heart failure, compliance appears more predictive than PVR, because it incorporates the effect of pulsatile loading caused by elevated left side filling pressures [13, 52] . Despite their prognostic value, both PVR and compliance are measures of afterload and do not directly reflect RV function.
Measures of right ventricular-pulmonary arterial coupling
The gold standard for the assessment of ventricular function and the effect of afterload is through the relation of ventricular pressure and volume. This type of analysis has been extensively performed in the LV, but the same principles also hold true for the RV [55,56]. By varying preload or afterload, a family of pressure-volume loops can be created, and the maximal ratio of pressure to volume (P/
where V o is the volume-intercept) can be determined for each loop. As opposed to the LV, the normal RV pressure-volume loop is triangular in shape ( Fig. 1a ) with pressure declining throughout ejection -indicative of the low impedance vascular system. Therefore, this maximal ratio of pressure and volume may not occur near end-systole, making pressure-volume assessment more difficult. However, the shape of the RV pressure-volume loop changes to more of a square shape (similar to the LV) in mild pulmonary hypertension ( Fig. 1b) or even a trapezoidal shape in more severe pulmonary hypertension (Fig. 1c) , with pressure continuing to rise throughout ejection [57 & ]. In the latter two cases, the maximal ratio of pressure and volume will occur near end-systole as it does in the LV. The end-systolic pressure-volume relationship (ESPVR) can then be determined by connecting the end-systolic pressure (ESP) points of each pressure-volume loop, the slope of which is the endsystolic elastance (Ees) -a relatively load-independent measure of contractility. By comparison, TAPSE, RVFAC and RVEF are all load-dependent, and therefore do not directly measure intrinsic RV contractility. Afterload may be estimated via the pressurevolume loop as the effective arterial elastance -ESP divided by the SV. This 'lumped' parameter of afterload takes into account both resistive and pulsatile components and more completely describes total RV afterload than PVR alone. The ratio of these two elastances (Ees/arterial elastance) can then be used to illustrate ventricular-vascular coupling. Measures of coupling are particularly attractive because they may help identify subclinical right heart failure. Impaired RV-pulmonary artery (PA) coupling in systemic sclerosis-associated PAH compared with idiopathic PAH was recently shown via this technique when other imaging and hemodynamic variables failed to discriminate between the two groups [57 & ].
Although certainly feasible, these types of invasive measures require specialized equipment and significant expertise, and are not practical for routine clinical use. Therefore, less invasive ways to measure RV-PA coupling are currently being sought. One of these approaches uses a single, steady-state pressure-volume loop to estimate Ees, negating the need for load variation and multibeat measures (so-called 'single beat' methods). First proposed by Brimioulle et al. [58] for the RV, one technique involves fitting a sine wave to the isovolumic portions of the RV pressure tracing to determine P max (Fig. 2a) , the theoretical maximal pressure the RV could generate if ejecting into infinite load. Thus, a second point (P max , end-diastolic volume) along the ESPVR is determined and Ees can be calculated (Fig. 2b) . Although good correlation was found between estimated and actual P max in normotensive dogs, the technique was not sensitive to inotropic induced changes in contractility [59] and was not predictive of outcome in a recent human study [60 && ]. A second, even simpler estimation of Ees assumes the volume intercept of the ESPVR is zero (V o ¼ 0). In this case, Ees could be estimated as the ratio of ESP/end-systolic volume (ESV), and the ratio of elastances as SV/ESV [ 
MANAGEMENT OF RIGHT VENTRICULAR FAILURE
The optimum management of RVF remains elusive, especially when it comes to the choice of inotropic ]. Animal models of PAH provide some insight to support claims that inotropy in RVF (secondary to PAH) is best achieved with dobutamine because of improved coupling to adenylyl cyclase [70] . The potency of inotropes in the RV Langendorff model (in descending order) is dobutamine ¼ isoproterenol > dopamine > phenylephrine. Additionally, the superiority of dobutamine over dopamine may reflect the fact that dopamine relies heavily on dopamine-1 receptor signaling, which is impaired in RVH [70] .
Admission to an ICU for RVF and consequent inotropic support has an inpatient mortality rate of over 40% [71] . In this setting, and with the absence of standardized protocols, there has been some interest in developing mechanical circulatory support targeting the RV [72] . To this end, the Use of Impella RP Support System in Patients with Right Heart Failure (RECOVER) Right Study is ongoing (http://clinicaltrials.gov/show/NCT01777607) in patients who developed RVF within 48 h after implantation of an LVAD, or patients in postcardiotomy shock or patients with postacute myocardial infarction shock. The results of this study will provide insight into the ability to unload the RV.
Although there is downregulation and desensitization of adrenergic (b1-adrenoreceptor and a1-adrenoreceptor) receptors in RVF, there is increasing interest in the feasibility of the use of b-blockers in chronic RVF (likely not acute RVF, akin to the practice in left ventricular systolic dysfunction). Carvedilol can reverse established RVF in two different rat models of PAH, and the improvement in RV function is associated with improved capillary density and reduced hypertrophy of the myocardium [73] . Additionally, bisoprolol has been shown to delay progression toward RVF in an animal model of PAH, and can, at least in part, preserve RV systolic and diastolic function [74] . Of note, genes encoding proteins involved in the mitochondrial dysfunction pathway are upregulated in PAH animals treated with carvedilol and protein ubiquitination pathways, and genes encoding proteins 
CONCLUSION
The diagnosis and treatment of the RVF continue to be challenging. As our understanding of molecular mechanisms evolves, we should be able to offer more therapeutic options for this final common pathway. However, whether the therapeutic targets will be on the neuroendocrine system or metabolic modulators remains to be seen and will be dependent on insight offered by cellular studies as well as through intricate hemodynamics.
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